Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Oscar Fernández, Miguel Angel Calleja-Hernández, José Meca-Lallana, Celia Oreja-Guevara, Ana Polanco & Ferran Pérez-Alcántara. (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics & Outcomes Research 17:4, pages 321-333.
Read now
Read now
Wenqing Su, Anuraag Kansal, Colin Vicente, Baris Deniz & Sujata Sarda. (2016) The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Medical Economics 19:7, pages 718-727.
Read now
Read now
Aaron L Boster, Corey C Ford, Orit Neudorfer & Yossi Gilgun-Sherki. (2015) Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 15:6, pages 575-586.
Read now
Read now
Articles from other publishers (9)
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref
Crossref
Sen Lin. 2019. The Science and Regulations of Naturally Derived Complex Drugs. The Science and Regulations of Naturally Derived Complex Drugs
271
295
.
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser & Aileen Clarke. (2017) Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 21:52, pages 1-352.
Crossref
Crossref
Rainel Sánchez-de la Rosa, Laura García-Bujalance & José Meca-Lallana. (2015) Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review 5:1.
Crossref
Crossref
Livio Garattini, Francesca Ghislandi & Milene Rangel Da Costa. (2015) Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?. PharmacoEconomics 33:12, pages 1241-1244.
Crossref
Crossref